T cell modulation of COVID-19 disease
T cell modulation of COVID-19 disease
批准号:
10674085
负责人:
Nicholas James Maness
金额:
$21.88万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-20 至 2024-08-31
关键词:
2019-nCoVAcute Respiratory Distress SyndromeAnimalsAntibodiesAntiviral AgentsBloodBlood Coagulation DisordersCD8-Positive T-LymphocytesCD8B1 geneCOVID-19COVID-19 pandemicCellsCessation of lifeComplementComplexCoronavirusDataDiseaseDisease OutcomeDisease ProgressionDisease modelEndothelial CellsExhibitsFutureGenerationsGeneticHumanHyperactivityImmuneImmune System DiseasesImmune responseIn VitroIndividualInfectionInfiltrationInflammatoryInflammatory ResponseInterleukin-6InvestigationKnowledgeLungMacacaMacaca mulattaMeasuresMediator of activation proteinModelingMonoclonal AntibodiesMyeloid CellsNatural Killer CellsPatientsPharmaceutical PreparationsPlayPneumoniaProteinsProtocols documentationResearchRoleSARS-CoV-2 infectionSamplingSiteSocietiesSymptomsT cell responseT-Cell DepletionT-LymphocyteTestingTherapeuticTimeVaccinesViralVirusanti-viral efficacyantigen-specific T cellscohortcytokineimmunogenicityimmunoregulationinterestmacrophageneutralizing antibodynonhuman primatenovel coronavirusnovel therapeuticsnovel vaccinespreclinical trialpreventrational designremdesivirresponsetherapy designvaccine platform
中文摘要
项目概要/摘要
2019年底出现的新型冠状病毒(SARS-CoV-2)迅速在世界各地传播
到目前为止,已经感染了数百万人,杀死了数十万人。这种病毒非常复杂,
大多数受感染的个体几乎没有明显的症状(尽管一些数据表明他们可能有
虽然是长期的伤害,但基本上是健康的。相比之下,一小部分感染者表现出
一系列严重的症状,包括肺炎,急性呼吸窘迫,凝血障碍,甚至
死亡轻度与重度症状的机制尚未完全了解,但免疫
机制似乎发挥了作用。因此,我们需要了解特定免疫细胞的作用,
了解疾病并正确治疗。特别感兴趣的是CD 8 T细胞(CTL)在疾病中的作用
结果。在这个项目中,我们将使用SARS-CoV-2感染的恒河猴模型来评估
CTL和其他CD 8+细胞在疾病中的重要性。在目标1中,我们将耗尽动物的所有细胞,
CD 8a分子,包括CTL和NK细胞,并评估它们清除病毒的能力。在目标2中,我们
仅靶向CTL进行消耗并同样评估其重要性。在目标3中,我们将在实验室中使用细胞,
评估CTL如何与病毒感染的细胞相互作用。该项目将全面评估
CTL在COVID-19疾病中的重要性或对其的保护。
英文摘要
Project Summary/Abstract
The novel coronavirus that emerged in late 2019, termed SARS-CoV-2, quickly spread throughout the world
and has, to date, infected millions and killed hundreds of thousands. This virus is shockingly complex in that
the majority of infected individuals show few overt symptoms (though some data suggest they may have
lasting damage nonetheless) but are largely healthy. In contrast, a small fraction of infected individuals exhibit
a range of serious symptoms including pneumonia, acute respiratory distress, clotting disorders, and even
death. The mechanisms that underly mild versus severe symptoms are not fully understood but immune
mechanisms appear to play a role. Thus, we need to understand the roles of particular immune cells in order to
understand the disease and properly treat it. Of particular interest is the role of CD8 T cells (CTL) in disease
outcome. In this project we will use the rhesus macaque model of SARS-CoV-2 infection to assess the
importance of CTL and other CD8+ cells in disease. In aim 1, we will deplete animals of all cells that express
the CD8a molecule, including CTL and NK cells, and assess their ability to clear the virus. In aim 2, we will
target only CTL for depletion and likewise assess their importance. In aim 3, we will use cells in the lab to
assess how CTL interact with virus infected cells. Together, this project will comprehensively assess the
importance of CTL in COVID-19 disease or protection from it.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pan Coronavirus Genomic Surveillance of a Large NHP Colony
-
批准号:10575848
-
项目类别:
-
资助金额:$8.75万
-
财政年份:2022
-
负责人:Nicholas James Maness
-
依托单位:
T cell modulation of COVID-19 disease
-
批准号:10239822
-
项目类别:
-
资助金额:$25.5万
-
财政年份:2021
-
负责人:Nicholas James Maness
-
依托单位:
T cell modulation of COVID-19 disease
-
批准号:10491340
-
项目类别:
-
资助金额:$21.25万
-
财政年份:2021
-
负责人:Nicholas James Maness
-
依托单位:
Reservoir modulation by Nef and anti-nef CTL
-
批准号:9927138
-
项目类别:
-
资助金额:$25.5万
-
财政年份:2020
-
负责人:Nicholas James Maness
-
依托单位:
Reservoir modulation by Nef and anti-nef CTL
-
批准号:10261352
-
项目类别:
-
资助金额:$21.25万
-
财政年份:2020
-
负责人:Nicholas James Maness
-
依托单位:
Focused characterization of non-canonical T cells against SIV
-
批准号:9560521
-
项目类别:
-
资助金额:$25.5万
-
财政年份:2018
-
负责人:Nicholas James Maness
-
依托单位:
SIV antisense epitopes as novel markers of latency
-
批准号:8846907
-
项目类别:
-
资助金额:$25.35万
-
财政年份:2015
-
负责人:Nicholas James Maness
-
依托单位:
海外基金